Peer-reviewed veterinary case report
Epirubicin chemotherapy outcomes in dogs with histiocytic sarcoma
By Mason, S L et al.·Published in Veterinary and comparative oncology·2018·Queens Veterinary School Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with histiocytic sarcoma, a type of cancer, were treated with two chemotherapy drugs: lomustine and epirubicin. Out of 29 dogs, about 29% showed a positive response to epirubicin, with some experiencing a median time of about 69 days before the cancer progressed. For those receiving epirubicin as a rescue treatment after lomustine, the response rate was lower at 19%, but the treatment still helped some dogs live longer, with a median survival time of 185 days. This suggests that combining these two drugs can be beneficial for dogs with this aggressive cancer.
People also search for: dog histiocytic sarcoma treatment · epirubicin for dogs cancer · lomustine chemotherapy for dogs
Abstract
The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of HS that were treated with both lomustine and epirubicin were retrospectively evaluated. Of 29 dogs receiving epirubicin alternating with, or subsequent to lomustine treatment, including in a rescue setting, response to epirubicin could be assessed in 20 with an overall response rate (ORR) of 29% and biological response rate (BRR) of 71%. Median time to progression (TTP) in 12 of these 20 dogs in which it was assessable was 69 days (range: 40-125 days). For dogs treated in the rescue setting epirubicin specific ORR was 19% and BRR 63%. Median TTP in the 9 of these 16 dogs in which it was assessable was 62 days (range: 40-125 days). Median survival time for all dogs treated with both epirubicin and lomustine was 185 days (range: 27-500 days). Some dogs with HS respond to epirubicin and dogs treated with combinations of epirubicin and lomustine have modestly improved survival times compared with single agent studies, and similar to dogs with HS treated with alternating lomustine and doxorubicin. Single agent epirubicin is also a valid short term rescue therapy for canine HS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28621004/